H.C. Wainwright lowered the firm’s price target on Sensus Healthcare (SRTS) to $8 from $12 and keeps a Buy rating on the shares. The firm cites the company’s Q2 sales miss for the target cut.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRTS:
- Sensus Healthcare price target lowered to $6 from $13 at Lake Street
- Sensus Healthcare Reports Q2 2025 Financial Results
- Sensus Healthcare reports Q2 EPS (6c), consensus 1c
- Sensus Healthcare superficial radiation therapy systems get MDSAP certification
- Sensus Healthcare enters strategic agreement with Radiology Oncology Systems